At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- No Intervention (other)
- How long the study runs
- Study runs about 14 months (dates as stated)
- About the drug or intervention
- No Intervention — other: This is a non-interventional study.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at adults with kidney failure or severe long-term kidney disease who developed a cytomegalovirus (CMV) infection after having an organ or stem cell transplant. CMV is a common virus that can cause problems in people whose immune systems are weak. The study follows people who were already given a medicine called maribavir as part of their normal care because their CMV infection did not get better with earlier treatment.
Who can take part
- Adults aged 18 or over
- Diagnosed with kidney failure (end-stage renal disease) or severe long-term kidney disease before the study period
- If kidney failure: confirmed by a kidney filter rate (eGFR) under 15 mL/min/1.73m², including people on dialysis
- If severe long-term kidney disease: confirmed by a kidney filter rate (eGFR) of 15 to under 30 mL/min/1.73m²
- Had a solid organ transplant or a blood stem cell transplant before the study period
- Diagnosed with a CMV infection after transplant that did not respond to earlier treatment (with or without resistance)
- Started treatment with maribavir as part of normal care during the study period and received at least one dose
- Gave informed consent where local rules require it, before any data was collected
Who may not be able to
- Not stated — ask your trial team (the study lists no reasons that would exclude someone)
What taking part involves
- • Taking maribavir, a medicine for CMV, as prescribed in normal practice (at least one dose)
Time commitment: Not stated — ask the trial team what taking part involves, including any visits and how long the study lasts.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 10
- Started
- 2025-11-03
- Last checked
- 2025-12
Plain English Summary
What is this study?
- • Testing a new treatment for cytomegalovirus (cmv)
- • Clinical study - 10 participants
- • The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with cytomegalovirus (cmv)
Where?
- • Dorchester - Dorset County Hospital
- • Birmingham - Queen Elizabeth Hospital Birmingham
- • London - King's College Hospital
- • Wrexham - Wrexham Maelor Hospital
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis). In this study, already existing data will be collected from the participant's medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
Treatment history
Treatments you must have had:
- ✓ by local regulations)
What the study is looking for
- ✓Adults more than and equal to (≥) 18 years of age at index date.
- ✓Diagnosis of comorbid ESRD or comorbid severe CKD prior to the index date.
- ✓If severe CKD: participant diagnosed with severe CKD confirmed by an eGFR of 15 to \<30 mL/min/1.73m\^2 at index.
- ✓Participant has undergone solid organ transplant (SOT) or hematopoietic stem cell transplantation (HSCT) before...
- ✓Participant was diagnosed with refractory (with or without resistance) CMV during the latest post-transplant period.
Who cannot take part
- ✗There are no exclusion criteria for this study.
See the full criteria
Where Is This Study? (4 UK sites)
Dorset County Hospital
Dorchester DT1 2JY, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham B15 2GW, United Kingdom
King's College Hospital
London SE5 9RS, United Kingdom
Wrexham Maelor Hospital
Wrexham LL13 7TD, United Kingdom
How to Get in Touch
Takeda Contact
Sponsor contactCONTACT